+ rigg 1 13b8.2
DESCRIPTION
Fig.3. A. 4 h-treatment. 10 min-treatment. 40. Non-permeabilized Jurkat T cells. + rIgG 1 13B8.2. 11%. + rIgG 1 13B8.2. Events. 10 2. 10 2. 10 1. 10 0. 10 1. 10 0. 21%. 0. Permeabilized Jurkat T cells. 40. + rIgG 1 13B8.2. + rIgG 1 13B8.2. 50%. Events. 73%. 10 2. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: + rIgG 1 13B8.2](https://reader036.vdokument.com/reader036/viewer/2022082820/568143f9550346895db08a27/html5/thumbnails/1.jpg)
+ rIgG1
13B8.2
100 101 102 100 101 102
Anti-ceramide antibody
Eve
nts
0
40
Non-permeabilizedJurkat T cells
PermeabilizedJurkat T cells
10 min-treatment 4 h-treatment
+ rIgG1
13B8.2
+ rIgG1
13B8.2+ rIgG1
13B8.273%
21%
50%
11%
Eve
nts
A40
0100 101 102100 101 102
B
0
10
20
30
40
50
Cer
amid
e-po
siti
veJu
rkat
T c
ells
(%
)
Inhibitor - - FB1 FB1 Imi Imi Myr Myr- +rIgG1 13B8.2 +- - + - +
Fig.3